GenSight Biologics announced it has closed a private placement raising approximately €4 million through the issuance of 9,302,326 new ordinary shares at €0.43 per share. According to the company, the offering was subscribed by select investors including GenSight’s management team and board members.
The company said that the new shares represent about 6.2% of its share capital after the transaction. The private placement was executed under the provisions of article L. 225-138 of the French Commercial Code, allowing for the issuance of shares to a specified group without pre-emptive rights for existing shareholders.
According to GenSight Biologics, proceeds from the transaction will be used to fund working capital and general corporate purposes. The company claims that this financing will help advance its clinical and commercial activities, which focus on gene therapies for retinal neurodegenerative diseases.
Settlement and delivery of the new shares took place on July 9, 2025. The company said that these shares are fully fungible with its existing shares and will be admitted to trading on Euronext Growth Paris.
GenSight Biologics noted that it continues to explore additional funding options to support its programs, which include LUMEVOQ® for Leber hereditary optic neuropathy and GS030 for retinitis pigmentosa. The company said that updates on further financing efforts will be provided in due course.
